HPOB 是一种高选择性HDAC6抑制剂，IC50为 56 nM，其选择性是其他 HDAC 的 30 倍以上。它提高 DNA 损伤抗癌药物在转化细胞中的有效性。 修改 分子式下标C17H18N2O4 Information HPOB is a potent, selectiveHDAC6inhibitor withIC50of 56 nM, >30-fold selectivity over other HDACs. Targets HDAC6 ; HDAC3 ; HDAC8 ; HDAC1 ; HDAC10 14965,56 nM; 1.7 μM; 2.8 μM; 2.9 μM; 3.0 μM In vitro In normal (HFS) and transformed (LNCaP, A549, and U87) cells, HPOB induces acetylation of α-tubulin, however, not histones, and inhibits cell growth, however, not viability. In HFS cells, HPOB enhances transformed cell death induced by etoposide, doxorubicin, or SAHA. HPOB also enhancing etoposide-induced transformed cell death via the apoptotic pathway in transformed cells. In vivo In mice bearing CWR22 human prostate cancer xenografts, HPOB (300 mg/kg/d i.p.), when in combination with SAHA, causes suppression of the growth of established tumors, while produces no significant suppression when used alone. Cell Research(from reference) Cell lines：HFS, A549, LNCaP, and U87 cells Concentrations：~32 μM Incubation Time：72 hours